2025 United States Anti-Infective Vaccines Market Revenue Opportunities Report
Description
The 2025 United States Anti-Infective Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States anti-infective vaccines market are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc. GlaxoSmithKline holds the largest market share of approximately 20-25%, having recently launched vaccines such as Arexvy targeting respiratory syncytial virus (RSV) and herpes zoster. Sanofi, with a 15-20% market share, introduced a new conjugate vaccine for meningococcal disease offering broader protection. Merck & Co. controls 12-15% of the market and in 2024 gained FDA approval for Capvaxive, a pneumococcal vaccine for adults over 50. Pfizer, with 10-12% market share, expanded its Prevnar 20 vaccine in 2025 to cover additional pneumococcal serotypes.
These companies are key players driving growth through innovations like mRNA, recombinant protein vaccines, and adjuvants, supported by strong government immunization programs in the U.S. The FDA’s Center for Biologics Evaluation and Research (CBER) oversees vaccine approval processes, ensuring vaccine safety and efficacy. Vaccines are recommended by the CDC through its Advisory Committee on Immunization Practices (ACIP), which evaluates and endorses vaccination schedules. Alongside these pharmaceutical giants, emerging players like Moderna are advancing novel mRNA vaccine candidates targeting influenza and RSV, reinforcing the competitive and innovative landscape in the U.S. anti-infective vaccines market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States anti-infective vaccines market are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc. GlaxoSmithKline holds the largest market share of approximately 20-25%, having recently launched vaccines such as Arexvy targeting respiratory syncytial virus (RSV) and herpes zoster. Sanofi, with a 15-20% market share, introduced a new conjugate vaccine for meningococcal disease offering broader protection. Merck & Co. controls 12-15% of the market and in 2024 gained FDA approval for Capvaxive, a pneumococcal vaccine for adults over 50. Pfizer, with 10-12% market share, expanded its Prevnar 20 vaccine in 2025 to cover additional pneumococcal serotypes.
These companies are key players driving growth through innovations like mRNA, recombinant protein vaccines, and adjuvants, supported by strong government immunization programs in the U.S. The FDA’s Center for Biologics Evaluation and Research (CBER) oversees vaccine approval processes, ensuring vaccine safety and efficacy. Vaccines are recommended by the CDC through its Advisory Committee on Immunization Practices (ACIP), which evaluates and endorses vaccination schedules. Alongside these pharmaceutical giants, emerging players like Moderna are advancing novel mRNA vaccine candidates targeting influenza and RSV, reinforcing the competitive and innovative landscape in the U.S. anti-infective vaccines market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
